Ross Douthat pens a solid challenge to Damon Linker at a debate hosted by TNR and pretty much covers all the bases you could want. He hits Linker for the inconsistency of tone, by turns scholarly and ...
Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback